ArticleJournal for immunotherapy of cancer2019

Tumor-targeted IL-12 combined with tumor resection yields a survival-favorable immune profile.

Qingnan Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.